查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813460

2032 年生物製藥許可市場預測：按交易類型、許可模式、開發階段、方式、應用、最終用戶和地區進行的全球分析

Biopharmaceutical Licensing Market Forecasts to 2032 - Global Analysis By Deal Type, Licensing Model, Stage of Development, Modality, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球生物製藥授權市場預計在 2025 年達到 2,405 億美元，到 2032 年將達到 2,5996 億美元，預測期內的複合年成長率為 40.5%。

生物製藥授權是一種正式協議，其中一方（授權人）將智慧財產權（通常是專利和專有技術）授予另一方（被授權人），用於開發、生產和商業化生物製藥。此類協議使公司能夠獲得創新治療方法，擴展其產品組合，並分擔與研發和監管核准相關的風險和成本。許可安排可以是排他性的，也可以是非排他性的，通常包含特許權使用費、里程碑付款和共同開發權等條款，以促進整個生物製藥價值鏈的策略合作。

專利懸崖和管線再填充

許可協議，尤其是對外授權，已成為將未充分利用的資產收益並縮短開發週期的策略工具。新興生物技術公司因其創新平台而日益受到追捧，這些平台提供的新型候選療法能夠填補大型製藥公司產品組合的空白。這種動態推動了交易的激增，尤其是在未滿足需求的領域。此外，維持競爭優勢的迫切性促使企業探索早期授權機會和合作研發模式。

估價和交易結構挑戰

確定早期技術的公平市場價值本身就很複雜，通常涉及推測性預測和有限的臨床數據。特許權使用費結構、里程碑付款和地理權利等因素會使談判更加複雜，這些因素可能會稀釋感知價值。規模較小的公司可能缺乏處理這些複雜問題的財務或法律專業知識，而規模較大的公司則擔心為未經證實的資產支付過高的費用。這些障礙可能會延遲或破壞有前景的合作關係，尤其是在競爭激烈的治療領域。

專注於利基、高價值治療領域

許可活動日益集中於創新迅速、定價能力強的專業領域，例如罕見疾病、腫瘤學以及細胞和基因治療。由於競爭有限且未滿足的醫療需求較高，這些領域提供了頗具吸引力的回報。各公司正瞄準獲得孤兒藥和突破性療法認定的資產，以利用優惠的監管治療和快速核准途徑。這一趨勢正在重塑整個產業的投資組合策略。

宏觀經濟不穩定和缺乏實質審查

許可談判也可能因實質審查不足而受到影響，這可能導致意外的責任、智慧財產權糾紛以及協議達成後的臨床挫折。在競爭日益激烈的背景下，一些公司在沒有充分評估監管風險、生產擴充性和市場進入障礙的情況下倉促達成交易。這可能導致代價高昂的重新談判和失敗的合作。確保嚴謹的技術、法律和商業性評估對於降低這些風險並維持長期價值創造至關重要。

COVID-19的影響：

疫情加速了人們對感染疾病平台和數位療法的興趣，再形成了許可格局。儘管臨床試驗和監管審查的早期中斷減緩了交易流程，但開發新冠相關療法和診斷方法的迫切需求導致許可交易激增，尤其是在mRNA技術和抗病毒藥物候選藥物方面。遠端協作工具和虛擬實質審查流程已成為常態，簡化了跨國交易。

預計在預測期內，對外授權業務將佔據最大佔有率

預計在預測期內，轉出授權業務將佔據最大的市場佔有率，因為它在非核心資產收益和擴大市場覆蓋範圍方面發揮戰略作用。這種模式使原廠公司能夠利用外部專業知識進行臨床開發和商業化，尤其是在缺乏基礎設施的地區。這種模式尤其受到尋求前期投資和風險共擔的生物技術公司的青睞，活性化了對外授權業務的發展，使其成為最佳化投資組合和全球擴張的良好途徑。

細胞和基因治療（CGT）領域預計在預測期內實現最高複合年成長率

預計在預測期內，細胞和基因治療 (CGT) 領域將呈現最高成長率，這得益於再生醫學、免疫腫瘤學和個人化治療領域的突破。隨著各公司尋求獲得專有載體、生產平台和遞送技術，該領域的授權交易正在激增。儘管監管和生產要求複雜，但較高的臨床成功率和溢價潛力使 CGT 資產在許可方面極具吸引力。

佔比最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其強大的創新生態系統、良好的智慧財產權框架和強勁的創業投資活動。該地區擁有眾多生物技術中心、學術研究中心和監管機構，為交易撮合提供了便利。美國公司在授權和跨境合作方面特別活躍，充分利用其先進的研發能力和全球網路。

複合年成長率最高的地區：

預計北美將在預測期內實現最高的複合年成長率，這反映出該地區擁有充滿活力的研發管線，並積極關注新型療法。該地區對精準醫療、數位健康整合和快速核准途徑的關注，正吸引全球對美國原產藥物許可的興趣。研發稅收優惠和簡化監管流程等策略性政策舉措正在進一步加快交易速度。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球生物製藥許可市場（按交易類型）

  • 引入授權
  • 轉出授權
  • 共同開發
  • 合資企業
  • 生產許可證
  • 其他交易類型

6. 全球生物製藥許可市場（按許可模式）

  • 獨家許可
  • 特定領域的許可證
  • 非獨佔許可

7. 全球生物製藥許可市場（依發展階段）

  • 發現和臨床前階段
  • 第一階段
  • 第二階段
  • 第三階段
  • 商業化/市場產品階段

8. 全球生物製藥許可市場（按方式）

  • 單株抗體（mAb）和生物製藥
  • 細胞和基因治療（CGT）
  • mRNA和核酸療法
  • 疫苗
  • 生技藥品衍生小分子
  • 重組蛋白
  • 其他方式

9. 全球生物製藥許可市場（按應用）

  • 腫瘤學
  • 免疫學
  • 感染疾病
  • 心血管疾病
  • 神經系統疾病
  • 代謝和內分泌紊亂
  • 罕見疾病
  • 其他用途

第 10 章：全球生物製藥許可市場（按最終用戶分類）

  • 生技和中型企業
  • 合約研究組織
  • 合約開發和製造組織
  • 學術研究機構
  • 其他最終用戶

第 11 章：全球生物製藥許可市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • Novartis
  • Pfizer
  • Roche
  • Johnson & Johnson
  • Merck & Co.
  • AstraZeneca
  • Sanofi
  • GlaxoSmithKline（GSK）
  • AbbVie
  • Bristol-Myers Squibb（BMS）
  • Amgen
  • Eli Lilly & Company
  • Takeda Pharmaceutical Company
  • Gilead Sciences
  • Regeneron Pharmaceuticals
  • Biogen
  • Vertex Pharmaceuticals
  • Moderna
  • Bayer AG
  • Incyte Corporation
Product Code: SMRC30909

According to Stratistics MRC, the Global Biopharmaceutical Licensing Market is accounted for $240.5 billion in 2025 and is expected to reach $2,599.6 billion by 2032 growing at a CAGR of 40.5% during the forecast period. Biopharmaceutical licensing is a formal agreement wherein intellectual property rights typically patents or proprietary technologies are granted by one party (licensor) to another (licensee) for development, manufacturing, or commercialization of biologic-based products. These arrangements enable companies to access innovative therapies, expand portfolios, and share risks and costs associated with R&D and regulatory approval. Licensing may be exclusive or non-exclusive, and often includes provisions for royalties, milestone payments, and co-development rights, fostering strategic collaboration across the biopharma value chain

Market Dynamics:

Driver:

Patent cliffs and pipeline replenishment

Licensing agreements especially out-licensing have become strategic tools to monetize underutilized assets and accelerate development timelines. Emerging biotech firms are increasingly sought after for their innovative platforms, offering novel therapeutic candidates that can fill gaps in large pharma portfolios. This dynamic is fostering a surge in deal activity, particularly in areas with unmet clinical needs. Moreover, the urgency to maintain competitive advantage is driving companies to explore early-stage licensing opportunities and collaborative R&D models.

Restraint:

Valuation and deal structure challenges

Determining fair market value for early-stage technologies is inherently complex, often involving speculative forecasts and limited clinical data. Negotiations are further complicated by royalty structures, milestone payments, and territorial rights, which can dilute perceived value. Smaller firms may lack the financial or legal expertise to navigate these intricacies, while larger players are cautious about overpaying for unproven assets. These hurdles can delay or derail promising partnerships, especially in competitive therapeutic areas.

Opportunity:

Focus on niche and high-value therapeutic areas

Licensing activity is increasingly concentrated in specialized domains such as rare diseases, oncology, and cell & gene therapies, where innovation is rapid and pricing power remains strong. These segments offer attractive returns due to limited competition and high unmet medical needs. Companies are targeting assets with orphan drug designation or breakthrough therapy status to capitalize on regulatory incentives and expedited approval pathways. This trend is reshaping portfolio strategies across the industry.

Threat:

Macroeconomic instability & lack of due diligence

Licensing negotiations are also vulnerable to inadequate due diligence, which can result in unforeseen liabilities, IP disputes, or clinical setbacks post-deal. As competition intensifies, some firms may rush into agreements without fully assessing regulatory risks, manufacturing scalability, or market access barriers. This can lead to costly renegotiations or failed partnerships. Ensuring robust technical, legal, and commercial evaluations is critical to mitigating these risks and sustaining long-term value creation.

Covid-19 Impact:

The pandemic reshaped licensing dynamics by accelerating interest in infectious disease platforms and digital therapeutics. While initial disruptions in clinical trials and regulatory reviews slowed deal flow, the urgency to develop COVID-related treatments and diagnostics led to a spike in licensing agreements, particularly for mRNA technologies and antiviral candidates. Remote collaboration tools and virtual due diligence processes became standard, streamlining cross-border transactions.

The out-licensing segment is expected to be the largest during the forecast period

The out-licensing segment is expected to account for the largest market share during the forecast period due to its strategic role in monetizing non-core assets and expanding market reach. It enables originator companies to leverage external expertise for clinical development and commercialization, especially in regions where they lack infrastructure. This model is particularly favored by biotech firms seeking upfront capital and risk-sharing arrangements fueling out-licensing activity, making it the preferred route for portfolio optimization and global expansion.

The cell & gene therapies (CGT) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cell & gene therapies (CGT) segment is predicted to witness the highest growth rate driven by breakthroughs in regenerative medicine, immuno-oncology, and personalized therapies. Licensing deals in this space are surging as companies seek access to proprietary vectors, manufacturing platforms, and delivery technologies. High clinical success rates and premium pricing potential make CGT assets highly attractive for licensing, despite their complex regulatory and production requirements.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share attributed to robust innovation ecosystem, favorable IP frameworks, and strong venture capital activity. The region hosts numerous biotech hubs, academic research centers, and regulatory agencies that facilitate deal-making. U.S.-based companies are particularly active in out-licensing and cross-border collaborations, leveraging their advanced R&D capabilities and global networks.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR reflecting its dynamic pipeline and aggressive pursuit of novel therapies. The region's emphasis on precision medicine, digital health integration, and accelerated approval pathways is attracting global interest in licensing U.S.-originated assets. Strategic policy initiatives, such as tax incentives for R&D and streamlined regulatory processes, are further enhancing deal velocity.

Key players in the market

Some of the key players in Biopharmaceutical Licensing Market include Novartis, Pfizer, Roche, Johnson & Johnson, Merck & Co., AstraZeneca, Sanofi, GlaxoSmithKline (GSK), AbbVie, Bristol-Myers Squibb (BMS), Amgen, Eli Lilly & Company, Takeda Pharmaceutical Company, Gilead Sciences, Regeneron Pharmaceuticals, Biogen, Vertex Pharmaceuticals, Moderna, Bayer AG, and Incyte Corporation.

Key Developments:

In July 2025, AstraZeneca reported Priority Review & Breakthrough Therapy designation (US) for IMFINZI(R) in resectable early-stage gastric/gastroesophageal junction cancers. The company cited positive Phase 3 results and said the regulatory designations could accelerate patient access.

In July 2025, Novartis received approval for Coartem(R) Baby, the first malaria medicine formulated for newborns and very young infants. The company said this enables faster regulatory routes in African countries and expands access for the most vulnerable patients.

In June 2025, AbbVie announced a definitive agreement to acquire Capstan Therapeutics and later public filings/updates on the transaction. AbbVie said the deal adds an in-vivo tLNP CAR-T candidate and strengthens its immunology and cell-engineering capabilities.

Deal Types Covered:

  • In-Licensing
  • Out-Licensing
  • Co-Development
  • Joint Venture
  • Manufacturing Licenses
  • Other Deal Types

Licensing Models Covered:

  • Exclusive License
  • Field-Limited License
  • Non-Exclusive License

Stage of Developments Covered:

  • Discovery & Preclinical Stage
  • Phase I
  • Phase II
  • Phase III
  • Commercialization/Marketed Product Stage

Modalities Covered:

  • Monoclonal Antibodies (mAbs) & Biologics
  • Cell & Gene Therapies (CGT)
  • mRNA & Nucleic Acid Therapies
  • Vaccines
  • Small Biologics-Derived Molecules
  • Recombinant Proteins
  • Other Modalities

Applications Covered:

  • Oncology
  • Immunology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Diseases
  • Metabolic & Endocrine Diseases
  • Rare Diseases
  • Other Applications

End Users Covered:

  • Biotech & Mid-Caps
  • Contract Research Organizations
  • Contract Development & Manufacturing Organizations
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biopharmaceutical Licensing Market, By Deal Type

  • 5.1 Introduction
  • 5.2 In-Licensing
  • 5.3 Out-Licensing
  • 5.4 Co-Development
  • 5.5 Joint Venture
  • 5.6 Manufacturing Licenses
  • 5.7 Other Deal Types

6 Global Biopharmaceutical Licensing Market, By Licensing Model

  • 6.1 Introduction
  • 6.2 Exclusive License
  • 6.3 Field-Limited License
  • 6.4 Non-Exclusive License

7 Global Biopharmaceutical Licensing Market, By Stage of Development

  • 7.1 Introduction
  • 7.2 Discovery & Preclinical Stage
  • 7.3 Phase I
  • 7.4 Phase II
  • 7.5 Phase III
  • 7.6 Commercialization/Marketed Product Stage

8 Global Biopharmaceutical Licensing Market, By Modality

  • 8.1 Introduction
  • 8.2 Monoclonal Antibodies (mAbs) & Biologics
  • 8.3 Cell & Gene Therapies (CGT)
  • 8.4 mRNA & Nucleic Acid Therapies
  • 8.5 Vaccines
  • 8.6 Small Biologics-Derived Molecules
  • 8.7 Recombinant Proteins
  • 8.8 Other Modalities

9 Global Biopharmaceutical Licensing Market, By Application

  • 9.1 Introduction
  • 9.2 Oncology
  • 9.3 Immunology
  • 9.4 Infectious Diseases
  • 9.5 Cardiovascular Diseases
  • 9.6 Neurological Diseases
  • 9.7 Metabolic & Endocrine Diseases
  • 9.8 Rare Diseases
  • 9.9 Other Applications

10 Global Biopharmaceutical Licensing Market, By End User

  • 10.1 Introduction
  • 10.2 Biotech & Mid-Caps
  • 10.3 Contract Research Organizations
  • 10.4 Contract Development & Manufacturing Organizations
  • 10.5 Academic & Research Institutes
  • 10.6 Other End Users

11 Global Biopharmaceutical Licensing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Novartis
  • 13.2 Pfizer
  • 13.3 Roche
  • 13.4 Johnson & Johnson
  • 13.5 Merck & Co.
  • 13.6 AstraZeneca
  • 13.7 Sanofi
  • 13.8 GlaxoSmithKline (GSK)
  • 13.9 AbbVie
  • 13.10 Bristol-Myers Squibb (BMS)
  • 13.11 Amgen
  • 13.12 Eli Lilly & Company
  • 13.13 Takeda Pharmaceutical Company
  • 13.14 Gilead Sciences
  • 13.15 Regeneron Pharmaceuticals
  • 13.16 Biogen
  • 13.17 Vertex Pharmaceuticals
  • 13.18 Moderna
  • 13.19 Bayer AG
  • 13.20 Incyte Corporation

List of Tables

  • Table 1 Global Biopharmaceutical Licensing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Biopharmaceutical Licensing Market Outlook, By Deal Type (2024-2032) ($MN)
  • Table 3 Global Biopharmaceutical Licensing Market Outlook, By In-Licensing (2024-2032) ($MN)
  • Table 4 Global Biopharmaceutical Licensing Market Outlook, By Out-Licensing (2024-2032) ($MN)
  • Table 5 Global Biopharmaceutical Licensing Market Outlook, By Co-Development (2024-2032) ($MN)
  • Table 6 Global Biopharmaceutical Licensing Market Outlook, By Joint Venture (2024-2032) ($MN)
  • Table 7 Global Biopharmaceutical Licensing Market Outlook, By Manufacturing Licenses (2024-2032) ($MN)
  • Table 8 Global Biopharmaceutical Licensing Market Outlook, By Other Deal Types (2024-2032) ($MN)
  • Table 9 Global Biopharmaceutical Licensing Market Outlook, By Licensing Model (2024-2032) ($MN)
  • Table 10 Global Biopharmaceutical Licensing Market Outlook, By Exclusive License (2024-2032) ($MN)
  • Table 11 Global Biopharmaceutical Licensing Market Outlook, By Field-Limited License (2024-2032) ($MN)
  • Table 12 Global Biopharmaceutical Licensing Market Outlook, By Non-Exclusive License (2024-2032) ($MN)
  • Table 13 Global Biopharmaceutical Licensing Market Outlook, By Stage of Development (2024-2032) ($MN)
  • Table 14 Global Biopharmaceutical Licensing Market Outlook, By Discovery & Preclinical Stage (2024-2032) ($MN)
  • Table 15 Global Biopharmaceutical Licensing Market Outlook, By Phase I (2024-2032) ($MN)
  • Table 16 Global Biopharmaceutical Licensing Market Outlook, By Phase II (2024-2032) ($MN)
  • Table 17 Global Biopharmaceutical Licensing Market Outlook, By Phase III (2024-2032) ($MN)
  • Table 18 Global Biopharmaceutical Licensing Market Outlook, By Commercialization/Marketed Product Stage (2024-2032) ($MN)
  • Table 19 Global Biopharmaceutical Licensing Market Outlook, By Modality (2024-2032) ($MN)
  • Table 20 Global Biopharmaceutical Licensing Market Outlook, By Monoclonal Antibodies (mAbs) & Biologics (2024-2032) ($MN)
  • Table 21 Global Biopharmaceutical Licensing Market Outlook, By Cell & Gene Therapies (CGT) (2024-2032) ($MN)
  • Table 22 Global Biopharmaceutical Licensing Market Outlook, By mRNA & Nucleic Acid Therapies (2024-2032) ($MN)
  • Table 23 Global Biopharmaceutical Licensing Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 24 Global Biopharmaceutical Licensing Market Outlook, By Small Biologics-Derived Molecules (2024-2032) ($MN)
  • Table 25 Global Biopharmaceutical Licensing Market Outlook, By Recombinant Proteins (2024-2032) ($MN)
  • Table 26 Global Biopharmaceutical Licensing Market Outlook, By Other Modalities (2024-2032) ($MN)
  • Table 27 Global Biopharmaceutical Licensing Market Outlook, By Application (2024-2032) ($MN)
  • Table 28 Global Biopharmaceutical Licensing Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 29 Global Biopharmaceutical Licensing Market Outlook, By Immunology (2024-2032) ($MN)
  • Table 30 Global Biopharmaceutical Licensing Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 31 Global Biopharmaceutical Licensing Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 32 Global Biopharmaceutical Licensing Market Outlook, By Neurological Diseases (2024-2032) ($MN)
  • Table 33 Global Biopharmaceutical Licensing Market Outlook, By Metabolic & Endocrine Diseases (2024-2032) ($MN)
  • Table 34 Global Biopharmaceutical Licensing Market Outlook, By Rare Diseases (2024-2032) ($MN)
  • Table 35 Global Biopharmaceutical Licensing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 36 Global Biopharmaceutical Licensing Market Outlook, By End User (2024-2032) ($MN)
  • Table 37 Global Biopharmaceutical Licensing Market Outlook, By Biotech & Mid-Caps (2024-2032) ($MN)
  • Table 38 Global Biopharmaceutical Licensing Market Outlook, By Contract Research Organizations (2024-2032) ($MN)
  • Table 39 Global Biopharmaceutical Licensing Market Outlook, By Contract Development & Manufacturing Organizations (2024-2032) ($MN)
  • Table 40 Global Biopharmaceutical Licensing Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 41 Global Biopharmaceutical Licensing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.